AC Immune (ACIU) Competitors $2.05 -0.03 (-1.44%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$2.04 -0.01 (-0.49%) As of 07/15/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACIU vs. OCS, CMRX, CDMO, QURE, CRMD, CRON, GHRS, SNDX, IMNM, and GYREShould you be buying AC Immune stock or one of its competitors? The main competitors of AC Immune include Oculis (OCS), Chimerix (CMRX), Avid Bioservices (CDMO), uniQure (QURE), CorMedix (CRMD), Cronos Group (CRON), GH Research (GHRS), Syndax Pharmaceuticals (SNDX), Immunome (IMNM), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry. AC Immune vs. Its Competitors Oculis Chimerix Avid Bioservices uniQure CorMedix Cronos Group GH Research Syndax Pharmaceuticals Immunome Gyre Therapeutics AC Immune (NASDAQ:ACIU) and Oculis (NASDAQ:OCS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment. Which has more risk & volatility, ACIU or OCS? AC Immune has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, Oculis has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Is ACIU or OCS more profitable? AC Immune has a net margin of -177.79% compared to Oculis' net margin of -13,788.70%. AC Immune's return on equity of -44.60% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets AC Immune-177.79% -44.60% -22.25% Oculis -13,788.70%-92.95%-70.03% Do analysts recommend ACIU or OCS? AC Immune currently has a consensus price target of $12.00, suggesting a potential upside of 485.37%. Oculis has a consensus price target of $35.33, suggesting a potential upside of 97.50%. Given AC Immune's higher possible upside, equities analysts clearly believe AC Immune is more favorable than Oculis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AC Immune 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Oculis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in ACIU or OCS? 51.4% of AC Immune shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 4.6% of AC Immune shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media favor ACIU or OCS? In the previous week, AC Immune had 2 more articles in the media than Oculis. MarketBeat recorded 5 mentions for AC Immune and 3 mentions for Oculis. AC Immune's average media sentiment score of 1.37 beat Oculis' score of 0.62 indicating that AC Immune is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AC Immune 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oculis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation and earnings, ACIU or OCS? AC Immune has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAC Immune$28.30M7.27-$57.83M-$0.58-3.53Oculis$780K1,001.38-$97.43M-$2.64-6.78 SummaryAC Immune beats Oculis on 13 of the 15 factors compared between the two stocks. Get AC Immune News Delivered to You Automatically Sign up to receive the latest news and ratings for ACIU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACIU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACIU vs. The Competition Export to ExcelMetricAC ImmuneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$208.85M$2.96B$5.62B$9.30BDividend YieldN/A2.43%4.25%4.03%P/E Ratio-3.5320.2228.5719.58Price / Sales7.27289.98423.3593.84Price / CashN/A43.1536.0257.93Price / Book1.597.568.135.54Net Income-$57.83M-$55.11M$3.24B$257.73M7 Day Performance-1.44%3.81%0.16%-0.08%1 Month Performance5.67%11.60%5.95%8.09%1 Year Performance-47.16%-2.11%26.09%13.02% AC Immune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACIUAC Immune2.2043 of 5 stars$2.05-1.4%$12.00+485.4%-44.4%$208.85M$28.30M-3.53140News CoveragePositive NewsAnalyst RevisionGap UpOCSOculis2.0614 of 5 stars$18.74-1.4%$35.33+88.5%+53.7%$829.59M$780K-7.102CMRXChimerix0.5554 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.6241 of 5 stars$12.50+0.1%$12.25-2.0%+50.2%$799.18M$139.91M-5.23320High Trading VolumeQUREuniQure2.6982 of 5 stars$14.31-0.8%$37.82+164.3%+53.2%$789.86M$27.12M-3.26500CRMDCorMedix2.6757 of 5 stars$11.42-1.7%$17.14+50.1%+132.0%$788.13M$82.55M51.9130CRONCronos Group1.5818 of 5 stars$2.04flatN/A-15.1%$786.79M$117.61M15.69450GHRSGH Research1.5032 of 5 stars$15.01+0.7%$32.00+113.2%+37.1%$776MN/A-19.0010SNDXSyndax Pharmaceuticals3.0706 of 5 stars$8.73-3.0%$35.80+310.1%-62.2%$774.43M$23.68M-2.26110Analyst ForecastIMNMImmunome2.0071 of 5 stars$8.69-1.7%$23.33+168.5%-40.7%$769.19M$9.04M-2.7340News CoveragePositive NewsGYREGyre Therapeutics0.2244 of 5 stars$7.62-6.3%N/A-48.7%$762.25M$105.76M381.1940News Coverage Related Companies and Tools Related Companies Oculis Competitors Chimerix Competitors Avid Bioservices Competitors uniQure Competitors CorMedix Competitors Cronos Group Competitors GH Research Competitors Syndax Pharmaceuticals Competitors Immunome Competitors Gyre Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACIU) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AC Immune Please log in to your account or sign up in order to add this asset to your watchlist. Share AC Immune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
